Literature DB >> 9704016

A novel brain-specific isoform of beta spectrin: isolation and its interaction with Munc13.

G Sakaguchi1, S Orita, A Naito, M Maeda, H Igarashi, T Sasaki, Y Takai.   

Abstract

Munc13 is a component of the neurotransmitter release machinery which is specifically expressed in brain. Munc13 interacts with Doc2 and syntaxin which are also implicated in the neurotransmitter release process. Here we isolated another Munc13-interacting molecule from a rat brain cDNA library by use of the yeast two-hybrid system, identified it to be a novel type of beta spectrin, and named it beta SpIII sigma 1. beta SpIII sigma 1 was specifically expressed in brain, where it was enriched in the synaptic vesicle and plasma membrane fractions. Because spectrin has been shown to interact with the actin cytoskeleton which is involved in the exocytotic process, the present results suggest that the Munc13-beta SpIII sigma 1 interactions play a role in neurotransmitter release.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9704016     DOI: 10.1006/bbrc.1998.9067

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  19 in total

Review 1.  Membrane domains based on ankyrin and spectrin associated with cell-cell interactions.

Authors:  Vann Bennett; Jane Healy
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-08-19       Impact factor: 10.005

2.  Loss of beta-III spectrin leads to Purkinje cell dysfunction recapitulating the behavior and neuropathology of spinocerebellar ataxia type 5 in humans.

Authors:  Emma M Perkins; Yvonne L Clarkson; Nancy Sabatier; David M Longhurst; Christopher P Millward; Jennifer Jack; Junko Toraiwa; Mitsunori Watanabe; Jeffrey D Rothstein; Alastair R Lyndon; David J A Wyllie; Mayank B Dutia; Mandy Jackson
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

3.  Drosophila alpha- and beta-spectrin mutations disrupt presynaptic neurotransmitter release.

Authors:  D E Featherstone; W S Davis; R R Dubreuil; K Broadie
Journal:  J Neurosci       Date:  2001-06-15       Impact factor: 6.167

Review 4.  Cargo hold and delivery: Ankyrins, spectrins, and their functional patterning of neurons.

Authors:  Damaris N Lorenzo
Journal:  Cytoskeleton (Hoboken)       Date:  2020-02-14

5.  Targeted deletion of betaIII spectrin impairs synaptogenesis and generates ataxic and seizure phenotypes.

Authors:  Michael C Stankewich; Babette Gwynn; Thomas Ardito; Lan Ji; Jung Kim; Raymond F Robledo; Samuel E Lux; Luanne L Peters; Jon S Morrow
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

6.  Munc13-1 acts as a priming factor for large dense-core vesicles in bovine chromaffin cells.

Authors:  U Ashery; F Varoqueaux; T Voets; A Betz; P Thakur; H Koch; E Neher; N Brose; J Rettig
Journal:  EMBO J       Date:  2000-07-17       Impact factor: 11.598

7.  Beta-III spectrin mutation L253P associated with spinocerebellar ataxia type 5 interferes with binding to Arp1 and protein trafficking from the Golgi.

Authors:  Yvonne L Clarkson; Trudi Gillespie; Emma M Perkins; Alastair R Lyndon; Mandy Jackson
Journal:  Hum Mol Genet       Date:  2010-07-05       Impact factor: 6.150

Review 8.  Phorbol esters and neurotransmitter release: more than just protein kinase C?

Authors:  Eugene M Silinsky; Timothy J Searl
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

9.  A widely expressed betaIII spectrin associated with Golgi and cytoplasmic vesicles.

Authors:  M C Stankewich; W T Tse; L L Peters; Y Ch'ng; K M John; P R Stabach; P Devarajan; J S Morrow; S E Lux
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

10.  Spectrin mutations that cause spinocerebellar ataxia type 5 impair axonal transport and induce neurodegeneration in Drosophila.

Authors:  Damaris N Lorenzo; Min-gang Li; Sarah E Mische; Karen R Armbrust; Laura P W Ranum; Thomas S Hays
Journal:  J Cell Biol       Date:  2010-04-05       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.